Intravenous Infusions Ltd

The current share price of Intravenous Infusions Ltd (IIL) on the Ghana Stock Exchange (GSE) is GHS 0.11, as of Monday, June 15, 2026. The share price was unchanged from the prior session's close of GHS 0.11.

IIL has gained 37.5% over the past four weeks, ranking 2nd among all stocks listed on the Ghana Stock Exchange for the period.

Intravenous Infusions Ltd ranks 1st on the Ghana Stock Exchange by trading volume over the past three months (Apr 27 – Jun 15, 2026). A total of 51.56 million IIL shares worth GHS 4.16 million changed hands across 36 sessions, with an average daily turnover of 1.43 million shares (GHS 115.7 thousand). The busiest session saw 47.58 million shares trade on May 18th.

Intravenous Infusions Ltd (GSE: IIL) is a Healthcare company listed on the Ghana Stock Exchange since 2012, with a market capitalisation of GHS 4M.

Intravenous Infusions Limited (IIL) is a Ghanaian healthcare manufacturing company that produces sterile intravenous (IV) fluids and large-volume parenteral solutions for hospitals and healthcare facilities across Ghana and the West African sub-region. The company manufactures critical medical products including Normal Saline (0.9% sodium chloride), Dextrose solutions, Ringer's Lactate, and other IV fluids essential to patient care in surgical, emergency, and intensive care settings. IIL operates a WHO Good Manufacturing Practice (GMP)-certified manufacturing plant, enabling its products to meet the quality standards required for government hospital procurement and export to neighbouring countries. The company plays a vital role in Ghana's healthcare supply chain, reducing the country's reliance on imported IV fluids and supporting the local production goals set by Ghana's National Health Policy. Listed on the Ghana Stock Exchange since 2012, IIL is one of the very few healthcare manufacturing companies available to GSE investors. With a market capitalisation of approximately GHS 4 million, IIL is a micro-cap stock with low trading volumes. Investors interested in Ghana's long-term healthcare infrastructure development follow IIL as a pure-play domestic pharmaceutical manufacturer. Ticker: IIL.